FULC vs. NGNE, LRMR, KRRO, ALT, TVTX, ANRO, ANNX, SLRN, TBPH, and KALV
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Neurogene (NGNE), Larimar Therapeutics (LRMR), Korro Bio (KRRO), Altimmune (ALT), Travere Therapeutics (TVTX), Alto Neuroscience (ANRO), Annexon (ANNX), Acelyrin (SLRN), Theravance Biopharma (TBPH), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Fulcrum Therapeutics (NASDAQ:FULC) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 4.1% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 1.6% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Neurogene has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
Fulcrum Therapeutics presently has a consensus price target of $13.17, indicating a potential upside of 74.62%. Neurogene has a consensus price target of $48.25, indicating a potential upside of 42.16%. Given Fulcrum Therapeutics' higher possible upside, equities research analysts plainly believe Fulcrum Therapeutics is more favorable than Neurogene.
In the previous week, Neurogene had 16 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 21 mentions for Neurogene and 5 mentions for Fulcrum Therapeutics. Neurogene's average media sentiment score of 0.71 beat Fulcrum Therapeutics' score of 0.46 indicating that Neurogene is being referred to more favorably in the news media.
Fulcrum Therapeutics received 82 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 63.89% of users gave Fulcrum Therapeutics an outperform vote.
Neurogene has a net margin of 0.00% compared to Fulcrum Therapeutics' net margin of -3,470.05%. Neurogene's return on equity of -31.17% beat Fulcrum Therapeutics' return on equity.
Fulcrum Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Summary
Neurogene beats Fulcrum Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
